Updated results from the BEACON trial show unprecedented overall survival in the second-line treatment of CRC
Triplet targeted combination therapy appears to induce potent BRAF kinase signalling inhibition in patients with BRAFV600E-mutated metastatic colorectal cancer. Result from the BEACON study have shown for the first time that a combination of three…
Read More